Intersect ENT (XENT) Tops Q1 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/4/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMD, SMCI, SWKS, NRIX, TOST, BKNG
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
Intersect ENT (XENT) PT Raised to $22 at Northland Capital Markets; Medicare Cuts Not Hurting
May 3, 2017 12:25 PM EDTNorthland Capital Markets raised its price target on Intersect ENT (NASDAQ: XENT) to $22.00 (from $17.00) while maintaining a Outperform rating. The firm also raised FY18 numbers.
Analyst Suraj Kalia notes strong growth persists despite Medicare fears. Kalia said commentary indicated relatively muted effect on... More



